NCT07413666 A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years
| NCT ID | NCT07413666 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Centessa Pharmaceuticals (UK) Limited |
| Condition | Healthy Adult Male and Female Volunteers |
| Study Type | INTERVENTIONAL |
| Enrollment | 212 participants |
| Start Date | 2026-02-25 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 212 participants in total. It began in 2026-02-25 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.
Eligibility Criteria
Inclusion Criteria: * Healthy males or females as determined by assessments at the Screening Visit. * For Parts A, B, C, and D: Participants must be at least 18 years of age and no more than 60 years of age at the Screening Exclusion Criteria: * Presence of significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological, or psychiatric disease, as determined by medical history, physical examination, and screening investigations. * History of seizure disorder, any other condition that increases the risk of seizure * Has a clinically significant sleep disorder, including insomnia or sleep apnea
Contact & Investigator
ORX489 Centessa Program Lead ORX489 Centessa Program Lead
✉ ORX489-101study@centessa.com📞 617-468-5770
Frequently Asked Questions
Who can join the NCT07413666 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Healthy Adult Male and Female Volunteers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07413666 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07413666 currently recruiting?
Yes, NCT07413666 is actively recruiting participants. Contact the research team at ORX489-101study@centessa.com for enrollment information.
Where is the NCT07413666 trial being conducted?
This trial is being conducted at Lincoln, United States.
Who is sponsoring the NCT07413666 clinical trial?
NCT07413666 is sponsored by Centessa Pharmaceuticals (UK) Limited. The trial plans to enroll 212 participants.